FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984645442> ?p ?o ?g. }

• W1984645442 endingPage "20920" @default.
• W1984645442 startingPage "20915" @default.
• W1984645442 abstract "The experiments in this study were undertaken to determine whether inhibition of calpain activity in skeletal muscle is associated with alterations in muscle metabolism. Transgenic mice that overexpress human calpastatin, an endogenous calpain inhibitor, in skeletal muscle were produced. Compared with wild type controls, muscle calpastatin mice demonstrated normal glucose tolerance. Levels of the glucose transporter GLUT4 were increased more than 3-fold in the transgenic mice by Western blotting while mRNA levels for GLUT4 and myocyte enhancer factors, MEF 2A and MEF 2D, protein levels were decreased. We found that GLUT4 can be degraded by calpain-2, suggesting that diminished degradation is responsible for the increase in muscle GLUT4 in the calpastatin transgenic mice. Despite the increase in GLUT4, glucose transport into isolated muscles from transgenic mice was not increased in response to insulin. The expression of protein kinase B was decreased by ∼60% in calpastatin transgenic muscle. This decrease could play a role in accounting for the insulin resistance relative to GLUT4 content of calpastatin transgenic muscle. The muscle weights of transgenic animals were substantially increased compared with controls. These results are consistent with the conclusion that calpain-mediated pathways play an important role in the regulation of GLUT4 degradation in muscle and in the regulation of muscle mass. Inhibition of calpain activity in muscle by overexpression of calpastatin is associated with an increase in GLUT4 protein without a proportional increase in insulin-stimulated glucose transport. These findings provide evidence for a physiological role for calpains in the regulation of muscle glucose metabolism and muscle mass. The experiments in this study were undertaken to determine whether inhibition of calpain activity in skeletal muscle is associated with alterations in muscle metabolism. Transgenic mice that overexpress human calpastatin, an endogenous calpain inhibitor, in skeletal muscle were produced. Compared with wild type controls, muscle calpastatin mice demonstrated normal glucose tolerance. Levels of the glucose transporter GLUT4 were increased more than 3-fold in the transgenic mice by Western blotting while mRNA levels for GLUT4 and myocyte enhancer factors, MEF 2A and MEF 2D, protein levels were decreased. We found that GLUT4 can be degraded by calpain-2, suggesting that diminished degradation is responsible for the increase in muscle GLUT4 in the calpastatin transgenic mice. Despite the increase in GLUT4, glucose transport into isolated muscles from transgenic mice was not increased in response to insulin. The expression of protein kinase B was decreased by ∼60% in calpastatin transgenic muscle. This decrease could play a role in accounting for the insulin resistance relative to GLUT4 content of calpastatin transgenic muscle. The muscle weights of transgenic animals were substantially increased compared with controls. These results are consistent with the conclusion that calpain-mediated pathways play an important role in the regulation of GLUT4 degradation in muscle and in the regulation of muscle mass. Inhibition of calpain activity in muscle by overexpression of calpastatin is associated with an increase in GLUT4 protein without a proportional increase in insulin-stimulated glucose transport. These findings provide evidence for a physiological role for calpains in the regulation of muscle glucose metabolism and muscle mass. The presence of calpains, calcium-activated proteases, in mammalian cells was first reported over 30 years ago (1Guroff G. J. Biol. Chem. 1964; 239: 149-155Abstract Full Text PDF PubMed Google Scholar). Since that time at least 14 members of the calpain family have been identified and their chemistry and biology have been extensively studied (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar). It has been proposed that alterations in calpain activity result in a number of disease states, including stroke (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar, 3Wang K.K.W. Yuen P.-W. Trends Pharmacol. Sci. 1997; 15: 412-419Abstract Full Text PDF Scopus (271) Google Scholar), traumatic brain injury (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar, 3Wang K.K.W. Yuen P.-W. Trends Pharmacol. Sci. 1997; 15: 412-419Abstract Full Text PDF Scopus (271) Google Scholar), Alzheimer's disease (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar, 3Wang K.K.W. Yuen P.-W. Trends Pharmacol. Sci. 1997; 15: 412-419Abstract Full Text PDF Scopus (271) Google Scholar), cataracts (3Wang K.K.W. Yuen P.-W. Trends Pharmacol. Sci. 1997; 15: 412-419Abstract Full Text PDF Scopus (271) Google Scholar), limb-girdle muscular dystrophy (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar, 3Wang K.K.W. Yuen P.-W. Trends Pharmacol. Sci. 1997; 15: 412-419Abstract Full Text PDF Scopus (271) Google Scholar) and gastric cancer (2Haung Y. Wang K.K.W. Trends Mol. Med. 2001; 7: 355-362Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar). Recent studies of the genetic basis of type 2 diabetes revealed that genetic variation in calpain 10 accounted for a significant component of the genetic risk for diabetes in a Mexican-American population (4Horikawa Y. Oda N. Cox N.J. Li X. Melander M.O. Hara M. Hinokio Y. Lindner T.H. Mashima H. Schwarz P.E.H. Plata L.B. Horikawa Y. Oda Y. Yoshiuchi I. Colilla S. Polonsky K.S. Wei H. Concannon P. Iwasaki N. Shulze J. Baier L.J. Bogardus C. Groop L. Boerwinkle E. Hanis C.L. Bell G.I. Nat. Genet. 2000; 26: 163-175Crossref PubMed Scopus (1249) Google Scholar). Subsequent studies have confirmed the role of calpain 10 as a diabetes susceptibility gene in some (5Hanis C.L. Boerwinkle E. Chakraborty R. Ellsworth D.L. Concannon P. Stirling B. Morrison V.A. Wapelhorst B. Spielman R.S. GogolinEwens K.J. Shepard J.M. Williams S.R. Risch N. Hinds D. Iwasaki N. Ogata M. Omori Y. Petzold C. Reitzch H. Schroder H.E. Schulze J. Cox N.J. Menzel S. Boriraj V.V. Chen X. Lim L.R. Linder T. Mereu L.E. Wang Y.Q. Xiang K. Yamagta K. Yang Y. Bell G.I. Nat. Genet. 1996; 13: 161-166Crossref PubMed Scopus (554) Google Scholar) but not all (6Duggirala R. Blangero J. Aomasy L. Dyer T.D. Williams K.L. Leach R.J. O'Connell P. Stern M.P. Am. J. Hum. Genet. 1999; 64: 1127-1140Abstract Full Text Full Text PDF PubMed Scopus (297) Google Scholar, 7Mahtani M.M. Widen E. Lehto M. Thomas J. McCarthy M. Brayer J. Bryant B. Gayun C. Daly M. Forsblom C. Kanninen T. Kirby A. Kruglyak L. Munnelly K. Parkkonen M. Reeve-Daly M.P. Weaver A. Brettin T. Duyk G. Lander E.S. Groop L.C. Nat. Genet. 1996; 14: 90-94Crossref PubMed Scopus (321) Google Scholar, 8Harson R.L. Ehm M.G. Pettitt D.J. Prochazka M. Thompson D.B. Timberlake D. Foroud T. Kobes S. Baier L. Burns D.K. Almasy L. Blangero J. Garvey W.T. Bennett P.H. Knowler W.C. Am. J. Hum. Genet. 1998; 63: 1130-1138Abstract Full Text Full Text PDF PubMed Scopus (427) Google Scholar, 9Elbein S.C. Hoffman M.D. Teng K. Leppert M.F. Hasstedt S.J. Diabetes. 1999; 48: 1175-1182Crossref PubMed Scopus (275) Google Scholar, 10Hani E.H. Hager J. Philippi A. Demenais F. Froguel P. Vionnet N. Diabetes. 1997; 46: 1225-1226Crossref PubMed Scopus (26) Google Scholar, 11Thomas A.W. Sherratt E.J. Gagg J.W. Davies S.A. Majid A. Alcolado J.C. Hum. Genet. 1997; 101: 212-213Crossref PubMed Scopus (7) Google Scholar, 12Ciccarese M. Tonolo G. Delin I. Wong F.K. Holm P. Atzeni M.M. Lichtenstein P. Kockum I. Maioli M. Luthman H. Diabetologia. 1997; 40: 1366-1367Crossref PubMed Scopus (11) Google Scholar, 13Ghosh S. Hauser E.R. Magnuson V.L. Valle T. Ally D.S. Karanjawala Z.E. Rayman J.B. Knapp J.I. Musick A. Tannenbaum J. Te C. Eldridge W. Shapiro S. Musick T. Martin C. So A. Witt A. Harvan J.B. Watanabe R.M. Hagopian W. Eriksson J. Nylund S.J. Kohtamaki K. Tuomilehto-Wolf E. Toivanen L. Vidgren G. Ehnholm C. Bergman R.N. Tuomilehto J. Collins F.S. Boehnke M. J. Clin. Investig. 1998; 102: 704-709Crossref PubMed Scopus (22) Google Scholar) populations studied.The pathophysiological mechanism(s) whereby genetic variation in a calpain gene could lead to alterations in glucose tolerance are not known, and only a limited number of studies have examined the potential effects of alterations in calpain activity on insulin secretion or insulin action. These studies indicate that a reduction in calpain activity caused by calpain inhibitors induces a state of insulin resistance in isolated muscle strips (14Sreenan S.K. Zhou Y.P. Otani K. Hansen P.A. Currie K.P.M. Pan C.Y. Lee J.P. Ostrega D.M. Pugh W. Horikawa Y. Cox N.J. Hanis C.L. Burant C.F. Fox A.P. Bell G.I. Polonsky K.S. Diabetes. 2001; 50: 2013-2020Crossref PubMed Scopus (139) Google Scholar). Pancreatic islets exposed to calpain inhibitors for 4–6 h demonstrated increased glucose-induced insulin secretion, whereas longer periods of exposure induced significant defects in insulin secretory responses to glucose and other secretagogues (14Sreenan S.K. Zhou Y.P. Otani K. Hansen P.A. Currie K.P.M. Pan C.Y. Lee J.P. Ostrega D.M. Pugh W. Horikawa Y. Cox N.J. Hanis C.L. Burant C.F. Fox A.P. Bell G.I. Polonsky K.S. Diabetes. 2001; 50: 2013-2020Crossref PubMed Scopus (139) Google Scholar). These studies are limited by the fact that all experiments were conducted in vitro, and nonspecific effects of the calpain inhibitors, although unlikely, cannot be completely excluded. To examine the effects of inhibiting calpain activity using another in vivo experimental system, we produced transgenic mice that overexpress the endogenous calpain inhibitor, calpastatin.EXPERIMENTAL PROCEDURESGeneration of MCK-hCAST Transgenic Mice—Full-length human calpastatin (hCAST) 1The abbreviations used are: hCAST, human calpastatin; GLUT4, glucose transporter 4; MEF, myocyte enhancer factor; mMCK, mouse muscle-specific creatine kinase; EDL, extensor digitorum longus; WT, wild type; CsTg, calpastatin overexpression transgenic. corresponding to the 673-amino acid isoform described in GenBank™ accession number 1611327A was obtained using human pancreatic islet cDNA as template and amplified with forward and reverse primers 5′-TGG TGC AAC CAG CAA GTC TTC-3′ and 5′-GGA TGT TCA GAG ACT CAA C-3′, respectively. The PCR product was subcloned into pCR2.1-TOPO (Invitrogen) and the sequence of the insert confirmed. The insert was excised by digestion with EcoRI and cloned into the EcoRI site of the mouse muscle-specific creatine kinase (mMCK) promoter-bovine growth hormone (bGH) polyadenylation signal vector (15Zhu X. Hadhazy M. Groh M.E. Wheeler M.T. Wollmann R. McNally E.M. J. Biol. Chem. 2001; 276: 21785-21790Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar). The 4.28-kb mMCK-hCAST-bGH was excised from the vector by digestion with HhaI and purified by sucrose gradient centrifugation (Fig. 1). Transgenic mice were generated by microinjection of transgene DNA into the pronucleus of fertilized single-cell C57BL6 embryos at DNX Transgenic Sciences (Princeton, NJ). Animals were housed in a room maintained at 23 °C with a fixed 12-h light-dark cycle and given free access to Purina chow and water. After an overnight fast, mice were anesthetized by an intraperitoneal injection of pentobarbital sodium (5 mg/100 g body weight), and the soleus, epitrochlearis, extensor digitorum longus (EDL), and other muscles were excised. All experimental procedures were approved by the Washington University Animal Study Committee.DNA, RNA, and Protein Analysis—The mMCK-hCAST transgene was detected in transgenic mice by PCR analysis of tail DNA using forward and reverse primers 5′-GGC AAC GAG CTG AAA GCT CAT C-3′ and 5′-CAG TGA TAC CAG CAA CAC TCT CTC CAC C-3′. Total RNA was isolated from skeletal muscle using TRIzol reagent (Invitrogen) and suspended in Dnase- Rnase-free distilled water (Invitrogen). Mouse GLUT4 mRNA levels were determined by competitive RT-PCR using GLUT4 forward primer plus nested forward primer 5′-TCA ATG CCC CAC AGA AGG TGT CAA TGG TTG GGA AGG AAA AGG-3′ and reverse primer 5′-AAC CAG AAT GCC AAT GAC GAT G-3′ as described previously (34Garcia-Roves P.M. Han D.-H. Song Z. Jones T.E. Hucker K.A. Holloszy J.O. Am. J. Physiol. 2003; 285: E729-E736Crossref PubMed Scopus (72) Google Scholar).Total protein extracts were prepared by homogenizing muscle in 250 mm sucrose containing 20 mm HEPES and 1 mm EDTA, pH 7.4. Protein was resolved by SDS-PAGE and transferred to nitrocellulose membranes (Amersham Biosciences). The membranes were blocked overnight at 4 °C with 5% nonfat milk in phosphate-buffered saline containing 0.1% Tween 20. The membranes were probed with the following primary antibodies: polyclonal anti-CAST (Calbiochem, La Jolla, CA), anti-GLUT1 and -GLUT4 (a generous gift from Dr. Mike Mueckler, Washington University), anti-MEF 2A (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-MEF 2D (Transduction Laboratories, Lexington, KY) as well as anti-insulin receptor β subunit, anti-insulin receptor substrate-1, anti-insulin receptor substrate-2, monoclonal anti-Akt/PKB, and anti-phosphatidylinositol 3-kinase, all from Upstate Cell Signaling Solution, Lake Placid, NY. Horseradish peroxidase-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA), and reagents for enhanced chemiluminescence were obtained from Amersham Biosciences.Physiological Studies—Intraperitoneal glucose tolerance tests were performed following a 4-h fast. Blood was sampled from the tail vein prior to and 30, 60, and 120 min after injection of dextrose intraperitoneally (2 g/kg body weight). For glucose transport studies, epitrochlearis, soleus, and EDL muscles were removed and allowed to recover from dissection by incubation in 2 ml of Krebs-Henseleit buffer (KHB) containing 8 mm glucose, 32 mm mannitol, and 0.1% bovine serum albumin for 1 h at 35 °C in a shaking incubator. This was followed by 30 min of incubation in the same medium with or without a maximally effective insulin concentration (2 microunits/ml). The gas phase during the incubation was 95% O2, 5%CO2. The muscles were then washed for 10 min in KHB containing 40 mm mannitol, 0.1% bovine serum albumin, and insulin (if it was present in the previous incubation) to remove glucose from the extracellular space. Muscles were then transferred to 1.5 ml of KHB containing 3 mm 2-deoxy-d-[1,2-3H]glucose (2DG) (1.5 μCi/ml), 36 mm [14C]mannitol (0.2 μCi/ml), 0.1% bovine serum albumin, and insulin (if it was present in the previous incubation). Extracellular space and intracellular 2DG concentration were then determined as described previously (16Young D.A. Uhl J.J. Cartee G.D. Holloszy J.O. J. Biol. Chem. 1986; 261: 16049-16053Abstract Full Text PDF PubMed Google Scholar).Measurement of Muscle Weight—The soleus, EDL, tibialis anterior, gastrocnemius, and quadriceps muscles were dissected out using a consistent surgical approach. The muscles were weighed immediately following dissection after blood had been removed from the muscle surface.Measurement of Muscle Glycogen Content—Glycogen content was measured in perchloric acid extracts of muscle by the amyloglucosidase method (17Passonneau J.V. Lauderdale V.R. Anal. Biochem. 1974; 60: 405-412Crossref PubMed Scopus (625) Google Scholar).In Vitro Cleavage of Human GLUT4 by Calpain-2—Human GLUT4 (hGLUT4) protein was prepared using a coupled in vitro transcription and translation system (Promega, Madison, WI). One microgram of the hGLUT4-plasmid construct pGEM4Z-AMT7 (18Fukumoto H. Kayno T. Buse J.B. Edwards Y. Pilch P.F. Bell G.I. Seino S. J. Biol. Chem. 1989; 264: 7776-7779Abstract Full Text PDF PubMed Google Scholar) was incubated in the coupled transcription and translation reaction with 20 μCi of [35S]Met in a volume of 50 μl to generate [35S]-labeled hGLUT4. Unlabeled hGLUT4 was prepared by using 20 μm Met in the coupled transcription and translation reaction. Four microliters of the coupled transcription and translation reaction was incubated with 1.7 units of recombinant rat calpain-2 (Calbiochem) in 20 μl of calpain cleavage buffer (150 mm NaCl, 20 mm Tris-HCl (pH 7.4), 1 mm dithiothreitol, and 0.1% bovine serum albumin). Calpain was activated by addition of CaCl2 to 5 mm. Cleavage was terminated after 5 and 30 min by addition of 20 μl of SDS-sample buffer (0.125 m Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.2 m dithiothreitol, and 0.02% bromphenol blue). Samples were heated at 55 °C for 15 min and analyzed on a 4–20% SDS-PAGE followed by autoradiography or Western blotting. The Western blot was developed using a polyclonal anti-GLUT4 antibody generated using a cytoplasmic 12-amino acid C-terminal peptide from mouse GLUT4 (Alpha Diagnostic, San Antonio, TX).RESULTSGeneration of Transgenic Mice Overexpressing Calpastatin in Muscle—We obtained five founders (two females and three males). Human calpastatin was expressed in muscle (soleus and EDL) from all five founders. The founder used to generate the mice used in the present experiments showed a substantially greater level of calpastatin expression (∼20-fold) than the other founders, which all showed a similar level of overexpression. All transgenic mice were heterozygous. All were used around 4 months of age.Calpastatin Expression by Western Blot—Overexpression of human calpastatin in muscles was confirmed by Western blot (Fig. 2). Although human calpastatin was not expressed in muscle from WT mice, substantial expression was detected in transgenic (CsTg) mice.Fig. 2Muscle calpastatin expression. Overexpression of human calpastatin in muscles of CsTg but not WT mice was confirmed by Western blot.View Large Image Figure ViewerDownload (PPT)Mouse Body Weight and Glucose Tolerance—The body weights of male WT mice averaged 28.1 ± 0.6 g compared with 31.2 ± 0.5 g for the CsTg group (p <0.01, 8 mice per group, 23–25 weeks old). For the female mice, body weight averaged 21.8 ± 0.3 g for the WT group and 23.2 ± 0.4 g for the CsTg group (p <0.01, n = 16 per group, 23–25 weeks old). Differences in the intraperitoneal glucose tolerance test between the WT and the CsTg mice (WT versus CsTg: 182.3 ± 6.9 mg/dl versus 197.9 ± 9.3 mg/ dl at fasting, 189.3 ± 7.0 mg/ dl versus 198.3 ± 10.0 mg/ dl at 2 h after injection) were not statistically significant.Insulin Action in Muscle from CsTg Mice—The increase in 2-deoxy-d-[1,2-3H] glucose transport in response to a maximally effective insulin concentration (2 microunits/ml) was not significantly different in muscles from CsTg mice as compared with the WT controls in either EDL (Fig. 3), soleus (data not shown), or epitrochlearis (data not shown). Basal rates of glucose transport were also not different.Fig. 3Insulin-stimulated 2-deoxyglucose transport. EDL muscles were incubated in the absence or presence of insulin (2 microunits/ml). Values shown are means ± S.E. for seven muscles per group. There were no significant differences between the WT and the CsTg mice.View Large Image Figure ViewerDownload (PPT)GLUT4 Glucose Transporter Expression—As shown in Fig. 4, GLUT4 protein content of EDL, soleus, triceps, and tibialis anterior muscles was increased more than 3-fold in CsTg mice. The magnitude of insulin-stimulated muscle glucose transport is normally directly proportional to muscle GLUT4 content. This relationship is evident when muscle fiber types with different GLUT4 contents are compared (19Henriksen E.J. Bourey R.E. Rodnick K.J. Koranyi L. Permutt M.A. Holloszy J.O. Am. J. Physiol. 1990; 259: E593-E598Crossref PubMed Google Scholar), and in muscles that have undergone an adaptive increase in GLUT4 protein (20Weinstein S.P. Watts J. Haber R.S. Endocrinology. 1991; 129: 455-464Crossref PubMed Scopus (75) Google Scholar, 21Ren J.M. Semenkovich C.F. Holloszy J.O. Am. J. Physiol. 1993; 264: C146-C150Crossref PubMed Google Scholar, 22Ren J.-M. Semenkovich C.F. Gulve E.A. Gao J. Holloszy J.O. J. Biol. Chem. 1994; 269: 14396-14401Abstract Full Text PDF PubMed Google Scholar). Thus, the finding that stimulated glucose transport was the same in the CsTg as in the WT muscles despite 3-fold increases in the GLUT4 protein indicates that the increase in GLUT4 protein associated with calpastatin overexpression did not cause the expected increase in glucose transport in response to stimulation by insulin.Fig. 4Measurement of immunoreactive GLUT4. GLUT4 protein was determined by Western blotting in EDL, soleus, triceps, and tibialis anterior using a rabbit polyclonal antibody directed against the C terminus of GLUT4. Values are means ± S.E. for eight muscles per group. *, p <0.001; **, p <0.0001; #, p <0.00001; ##, p <0.000002 versus WT mice.View Large Image Figure ViewerDownload (PPT)GLUT4 mRNA Levels—Increases in GLUT4 expression induced by various adaptive stimuli may be mediated at the transcriptional level, as evidenced by an increased GLUT4 mRNA (23MacLean P.S. Zheng D. Jones J.P. Olson A.L. Dohm G.L. Biochem. Biophys. Res. Commun. 2002; 292: 409-414Crossref PubMed Scopus (67) Google Scholar). However, GLUT4 mRNA was significantly decreased in muscles from CsTg mice (Fig. 5), suggesting that the increase in GLUT4 protein was mediated by a post-transcriptional mechanism. Further support for this hypothesis is provided by the finding that MEF 2A and MEF 2D protein levels were decreased ∼50% in the CsTg muscles. Expression of GLUT4 in striated muscle is dependent on binding of a MEF 2A-MEF 2D heterodimer to the GLUT4 promoter (24Mora S. Pessin J.E. J. Biol. Chem. 2000; 275: 16323-16328Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). We have found that stimuli that induce increased GLUT4 expression also result in increases in MEF 2A and MEF 2D (25Ojuka E.O. Jones T.E. Nolte L.A. Chen M. Wamhoff B.R. Sturek M. Holloszy J.O. Am. J. Physiol. 2002; 282: E1008-E1013Crossref PubMed Scopus (177) Google Scholar). As shown in Fig. 6, A and B, both MEF 2A and MEF 2D were significantly decreased in muscles from CsTg mice compared with WT controls.Fig. 5Measurement of GLUT4 mRNA. The sequence of competitor RNA was identical to cDNA amplified by RT-PCR except for a 155-bp internal deletion (161–315). Mouse skeletal muscle total RNA was reverse-transcribed into cDNA and amplified using hybrid forward primer and reverse primer. Values are means ± S.E. for eight muscles per group. *, p <0.003.View Large Image Figure ViewerDownload (PPT)Fig. 6Measurement of immunoreactive MEF 2A and 2D. A, MEF 2A. B, MEF 2D. Myocyte enhancer factors MEF 2A and 2D were measured by Western blot. Expression of GLUT4 in striated muscle is dependent on binding of MEF 2A-2D heterodimer to the GLUT4 promoter. Values are means ± S.E. Triceps (n = 8), tibialis anterior (n = 8), and gastrocnemius (n = 6). *, p <0.05; **, p <0.01; ***, p <0.001.View Large Image Figure ViewerDownload (PPT)GLUT1 Glucose Transporter Expression—The finding that GLUT4 protein is increased in muscles of the CsTg mice, despite a decrease in GLUT4 mRNA, led us to hypothesize that GLUT4 is a calpain substrate and that inhibition of calpain by calpastatin is responsible for the increase in GLUT4. If this hypothesis is correct, one might also expect to see an increase in GLUT1 protein because its amino acid sequence is similar to that of GLUT4 (26Mueckler M. Eur. J. Biochem. 1994; 219: 713-725Crossref PubMed Scopus (944) Google Scholar). We, therefore, measured the GLUT1 protein level and found that it was also increased in skeletal muscle of the CsTg mice. Although highly significant (controls, 1.04 ± 0.14 versus CsTg, 1.66 ± 0.14 arbitrary units, mean ± S.E. for 16 muscles per group, p <0.004), the magnitude of the increase was smaller than that of GLUT4.Muscle Glycogen—Glucose transport is the primary ratelimiting step that determines the rate and extent of muscle glycogen accumulation (27Ren J.M. Marshall B.A. Gulve E.A. Gao J. Johnson D.W. Holloszy J.O. Mueckler M. J. Biol. Chem. 1993; 268: 16113-16115Abstract Full Text PDF PubMed Google Scholar). Increases in muscle GLUT4 are, therefore, generally associated with an increase in muscle glycogen content (20Weinstein S.P. Watts J. Haber R.S. Endocrinology. 1991; 129: 455-464Crossref PubMed Scopus (75) Google Scholar, 21Ren J.M. Semenkovich C.F. Holloszy J.O. Am. J. Physiol. 1993; 264: C146-C150Crossref PubMed Google Scholar, 22Ren J.-M. Semenkovich C.F. Gulve E.A. Gao J. Holloszy J.O. J. Biol. Chem. 1994; 269: 14396-14401Abstract Full Text PDF PubMed Google Scholar, 28Hansen P.A. Gulve E.A. Marshall B.A. Gao J. Pessin J.E. Holloszy J.O. Mueckler M. J. Biol. Chem. 1995; 270: 1679-1684Abstract Full Text Full Text PDF PubMed Google Scholar, 29Greiwe J.S. Hickner R.C. Hansen P.A. Racette S.B. Chen M.M. Holloszy J.O. J. Appl. Physiol. 1999; 87: 222-226Crossref PubMed Scopus (99) Google Scholar). Muscle glycogen concentrations were significantly increased in muscles of the CsTg mice, 20.4 ± 0.9 μmol/g EDL WT muscle compared with 46.0 ± 2.7 μmol/g EDL CsTg muscle.Effect of Muscle Glycogen Depletion on Glucose Transport— Accumulation of glycogen in muscle may induce insulin resistance. To determine whether the increase in glycogen in muscles from CsTg mice was masking an increase in muscle glucose transport in CsTg muscles, we exposed muscles to hypoxia for 80 min, a maneuver that reduces glycogen. The glucose concentration in the incubation medium for the CsTg muscles was also reduced compared with the incubations for the WT muscles (2 and 8 mm glucose, respectively). This approach markedly reduced glycogen concentrations to ∼7 μmol/g muscle wet weight. However, even after a reduction in muscle glycogen there were no significant differences in glucose transport induced by 2 microunits/ml insulin and hypoxia in the EDL and the soleus muscles of the CsTg compared with the WT mice (data not shown). Thus, the increase in GLUT4 resulting from calpain inhibition was not associated with a parallel increase in muscle glucose transport.Proteins of the Insulin Signaling Pathway—As a next step in our investigation of the mechanism responsible for the relative insulin resistance of the CsTg muscles, we measured the levels of some of the proteins of the insulin signaling pathway. Expression of the insulin receptor, insulin receptor substrates 1 and 2, and phosphatidylinositol 3-kinase proteins was similar in skeletal muscle of the transgenic and wild type mice (Fig. 7). However, there was a remarkable (∼60%) decrease in protein kinase B in skeletal muscle of the CsTg mice (Fig. 7). This finding could explain why insulin-stimulated glucose transport is not increased in CsTg muscle despite a ∼3-fold increase in GLUT4.Fig. 7Measurement of immunoreactive insulin receptor (IR), insulin receptor substrates (IRS) -1 and -2, protein kinase B (PKB), and phosphatidylinositol 3-kinase (PI 3-K). Values are means ± S.E. (n = 6, gastrocnemius muscle); *, p <0.0006.View Large Image Figure ViewerDownload (PPT)Cleavage of Human GLUT4 in Vitro by Calpain-2—To determine whether human GLUT4 is a calpain cleavage substrate, we incubated 35S-labeled recombinant hGLUT4 with purified calpain-2. The recombinant hGLUT4 has a mass of 43.7 kDa, and incubation with activated calpain-2 generated a protein with an estimated mass of 37.2 kDa (Fig. 8A). This fragment was not identified by an antibody that binds to an epitope at the C terminus of GLUT4 (Fig. 8B), suggesting the calpain-2 cleavage site is located in the C-terminal portion of GLUT4. The mass of the cleavage product suggests that the calpain-sensitive site is about 60–70 residues from the C terminus.Fig. 8Human GLUT4 is cleaved by calpain-2 in vitro. A, 35S-labeled recombinant hGLUT4 was incubated with calpain-2 for 5 and 30 min. The samples were subjected to SDS-PAGE and autoradiography. B, unlabeled recombinant GLUT4 was incubated with calpain-2. The GLUT4 protein was identified by Western blot using an anti-C-terminal GLUT4 antibody (αGLUT4). The arrowhead indicates the GLUT4 fragment generated on incubation with calpain-2.View Large Image Figure ViewerDownload (PPT)Effects on Muscle Mass—To determine whether overexpression of calpastatin affected muscle mass, muscles were systematically weighed in 23–25-week-old mice. Weight of EDL and soleus muscles was increased 12% (EDL, males), 33% (EDL, females), 17% (soleus, males), and 19% (soleus, females), respectively (Fig. 9A). Similar increases in mass were present in the other muscles, including the tibialis anterior (42% in males, 47% in females), gastrocnemius (13% in males, 14% in females), and quadriceps (21% in males, 14% in females) (Fig. 9B). Total muscle protein was increased in proportion to muscle weight in EDL (WT versus CsTg: 1.96 ± 0.10 mg versus 2.40 ± 0.10 mg, p <0.01) and soleus (WT versus CsTg: 1.58 ± 0.08 mg versus 1.85 ± 0.10 mg, p <0.05).Fig. 9Muscle weight. Muscles of 23–25-week-old mice were carefully dissected and weighed. Values are means ± S.E. for six to eight muscles per group. *, p <0.05; **, p < 0.0001.View Large Image" @default.
• W1984645442 created "2016-06-24" @default.
• W1984645442 creator A5002748082 @default.
• W1984645442 creator A5023979858 @default.
• W1984645442 creator A5041137849 @default.
• W1984645442 creator A5041424157 @default.
• W1984645442 creator A5042387811 @default.
• W1984645442 creator A5047445286 @default.
• W1984645442 creator A5063618672 @default.
• W1984645442 creator A5066512682 @default.
• W1984645442 creator A5067029691 @default.
• W1984645442 date "2004-05-01" @default.
• W1984645442 modified "2023-09-27" @default.
• W1984645442 title "Calpain System Regulates Muscle Mass and Glucose Transporter GLUT4 Turnover" @default.
• W1984645442 cites W1553733060 @default.
• W1984645442 cites W1565549817 @default.
• W1984645442 cites W1615935414 @default.
• W1984645442 cites W1718629903 @default.
• W1984645442 cites W1880398352 @default.
• W1984645442 cites W1971010898 @default.
• W1984645442 cites W1971185974 @default.
• W1984645442 cites W1976753246 @default.
• W1984645442 cites W1978263205 @default.
• W1984645442 cites W2012060810 @default.
• W1984645442 cites W2021323687 @default.
• W1984645442 cites W2043498565 @default.
• W1984645442 cites W2048667936 @default.
• W1984645442 cites W2058805992 @default.
• W1984645442 cites W2065225601 @default.
• W1984645442 cites W2067944947 @default.
• W1984645442 cites W2069791967 @default.
• W1984645442 cites W2069811002 @default.
• W1984645442 cites W2084321300 @default.
• W1984645442 cites W2087257007 @default.
• W1984645442 cites W2093567207 @default.
• W1984645442 cites W2107070633 @default.
• W1984645442 cites W2124900120 @default.
• W1984645442 cites W2138333803 @default.
• W1984645442 cites W2150468306 @default.
• W1984645442 cites W2155576825 @default.
• W1984645442 cites W2161381121 @default.
• W1984645442 cites W2169436026 @default.
• W1984645442 cites W2283880530 @default.
• W1984645442 cites W2421435187 @default.
• W1984645442 cites W4247885211 @default.
• W1984645442 doi "https://doi.org/10.1074/jbc.m400213200" @default.
• W1984645442 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15014085" @default.
• W1984645442 hasPublicationYear "2004" @default.
• W1984645442 type Work @default.
• W1984645442 sameAs 1984645442 @default.
• W1984645442 citedByCount "65" @default.
• W1984645442 countsByYear W19846454422012 @default.
• W1984645442 countsByYear W19846454422013 @default.
• W1984645442 countsByYear W19846454422014 @default.
• W1984645442 countsByYear W19846454422015 @default.
• W1984645442 countsByYear W19846454422016 @default.
• W1984645442 countsByYear W19846454422017 @default.
• W1984645442 countsByYear W19846454422018 @default.
• W1984645442 countsByYear W19846454422019 @default.
• W1984645442 countsByYear W19846454422020 @default.
• W1984645442 countsByYear W19846454422021 @default.
• W1984645442 countsByYear W19846454422022 @default.
• W1984645442 countsByYear W19846454422023 @default.
• W1984645442 crossrefType "journal-article" @default.
• W1984645442 hasAuthorship W1984645442A5002748082 @default.
• W1984645442 hasAuthorship W1984645442A5023979858 @default.
• W1984645442 hasAuthorship W1984645442A5041137849 @default.
• W1984645442 hasAuthorship W1984645442A5041424157 @default.
• W1984645442 hasAuthorship W1984645442A5042387811 @default.
• W1984645442 hasAuthorship W1984645442A5047445286 @default.
• W1984645442 hasAuthorship W1984645442A5063618672 @default.
• W1984645442 hasAuthorship W1984645442A5066512682 @default.
• W1984645442 hasAuthorship W1984645442A5067029691 @default.
• W1984645442 hasBestOaLocation W19846454421 @default.
• W1984645442 hasConcept C104317684 @default.
• W1984645442 hasConcept C134018914 @default.
• W1984645442 hasConcept C149011108 @default.
• W1984645442 hasConcept C161573976 @default.
• W1984645442 hasConcept C181199279 @default.
• W1984645442 hasConcept C185592680 @default.
• W1984645442 hasConcept C195580219 @default.
• W1984645442 hasConcept C2776188179 @default.
• W1984645442 hasConcept C2779306644 @default.
• W1984645442 hasConcept C3675279 @default.
• W1984645442 hasConcept C55493867 @default.
• W1984645442 hasConcept C56928146 @default.
• W1984645442 hasConcept C86803240 @default.
• W1984645442 hasConcept C95444343 @default.
• W1984645442 hasConceptScore W1984645442C104317684 @default.
• W1984645442 hasConceptScore W1984645442C134018914 @default.
• W1984645442 hasConceptScore W1984645442C149011108 @default.
• W1984645442 hasConceptScore W1984645442C161573976 @default.
• W1984645442 hasConceptScore W1984645442C181199279 @default.
• W1984645442 hasConceptScore W1984645442C185592680 @default.
• W1984645442 hasConceptScore W1984645442C195580219 @default.
• W1984645442 hasConceptScore W1984645442C2776188179 @default.
• W1984645442 hasConceptScore W1984645442C2779306644 @default.
• W1984645442 hasConceptScore W1984645442C3675279 @default.

• next